Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: Conference, Event, Webcast

ICON plc to Present at the 30th Annual Credit Suisse Healthcare Conference and the 4th Annual Evercore ISI HealthCONx Conference


ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at:

Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under "Events".

About ICON plc

ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 37,960 employees in 159 locations in 53 countries as at September 30, 2021. For further information about ICON, visit: www.iconplc.com and www.iconplc.com/pra.

This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, the impact of COVID-19 on our business, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain other reports, which are available on the SEC's website at http://www.sec.gov.

Source: ICON plc

ICON/ICLR-G


These press releases may also interest you

at 00:50
OKX, a leading Web3 technology company, has issued updates for April 25, 2024. OKX Wallet Now Integrated with XION, a User-First ...

at 00:30
Wego, the largest online travel marketplace in the Middle East and North Africa (MENA), is thrilled to announce its continued partnership with the Tourism Authority of Thailand (TAT) for the fourth consecutive year, showcasing the unparalleled beauty...

at 00:30
ENOC Group, a leading integrated global energy player, has appointed the innovative technology loyalty partner, Loyyal, to integrate Access Point, their self-service platform, into the Group's rewards programme. This move will revolutionize the 'YES'...

at 00:05
Systal Technology Solutions, a global managed network, cloud, and security transformation specialist, today announces the opening of its new Network Operations Center (NOC) in Tampa, Florida. This marks the latest milestone in Systal's recent growth...

at 00:05
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...

at 00:01
ATTOM, a leading curator of land, property, and real estate data, today released its first-quarter 2024 U.S. Home Sales Report, which shows that profit margins on median-priced single-family home and condo sales in the United States decreased to 55.3...



News published on and distributed by: